This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Inari Medical (NARI) Sues Truvic on Patent Infringement
by Zacks Equity Research
Inari Medical (NARI) files a patent infringement lawsuit against Imperative Care and its subsidiary Truvic over intentionally copying and overlapping the designs of Inari Medical's products.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Boston Scientific (BSX) due to its geographical expansions and impressive acquisitions.
Integer Holdings (ITGR) Gains 23.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Integer Holdings (ITGR) shares soar on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
by Zacks Equity Research
Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.
Boston Scientific (BSX) Up 1.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Centene (CNC), Cityblock Partner to Enhance Value-Based Care
by Zacks Equity Research
Centene (CNC) collaborates with Cityblock to provide comprehensive care services to Central Florida's Medicaid members.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock.
Boston Scientific (BSX) Rides on Emerging Markets, MedSurg
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Here's Why You Should Retain Inari Medical (NARI) for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
by Zacks Equity Research
Merit Medical's (MMSI) latest offering is likely to create an efficient approach to inflation, thereby providing improved patient care.
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
by Zacks Equity Research
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
DaVita (DVA) Gains 34.5% YTD: What's Driving the Stock?
by Zacks Equity Research
DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.
Three Reasons to Retain Inspire Medical (INSP) Stock for Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Philips' (PHG) Reports Positive AI-Powered Cardiac Study Data
by Zacks Equity Research
Philips' (PHG) AI-powered cardiac monitoring solutions demonstrate significantly lower re-admissions and a higher rate of survival in the retrospective study evaluating it in stroke patients.
Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment and continued geographical expansion.
Boston Scientific (BSX) mCRM System Study Outcome Favorable
by Zacks Equity Research
Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.
Veeva's (VEEV) Vault Basics to Boost Efficiency for Biotechs
by Zacks Equity Research
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
by Zacks Equity Research
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
HealthEquity (HQY) Closes Conduent's BenefitWallet Acquisition
by Zacks Equity Research
HealthEquity (HQY) completes the acquisition of Conduent's BenefitWallet HSA portfolio. This is likely to further strengthen the HSA business of HealthEquity.
Centene (CNC) to Continue Serving Kansas' Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Veeva System's (VEEV) strong product demand and strategic deals raise optimism about the stock.
GE HealthCare (GEHC), Medis Medical Partner to Aid CAD Therapy
by Zacks Equity Research
GE HealthCare (GEHC) and Medis Medical collaborate to boost precision care for coronary artery disease treatment.